PPD, Schrödinger, Beam set terms for IPO; FDA expands use of Merck's Dificid
→ With slower rates of patient enrollment than expected for their Phase III trial of its PARP inhibitor pamiparib vs placebo — as a therapy in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
